FDA to review supplemental new drug application for Bristol-Myers and Pfizer’s Eliquis
The application included data from the ADVANCE-1, ADVANCE-2, and ADVANCE-3 trials, which assessed the safety and efficacy of Eliquis against enoxaparin as a part of the EXPANSE clinical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.